Dr Reddy’s launches migraine management device Nerivio in Germany

Introduction: The launch marks the company’s entry into the realm of digital therapeutics in Europe. Nerivio will be showcased at the International Headache Society 2024 iHEAD meeting in Berlin in May 2024.

Byline: TheDialog

Article: Pharma major Dr Reddy‘s Laboratories has announced the launch of its drug-free migraine management device Nerivio in Germany through its subsidiary betapharm.

According to the company’s statement, the launch marks the company’s entry into the realm of digital therapeutics in Europe.

Nerivio has gained approval from the United States Food and Drug Administration (USFDA) and is also CE-mark certified in Europe.

The non-invasive device made its debut in 2023 at the DGN Kongress organized by the German Association of Neurology in Berlin, and the 17th European Headache Congress held in Barcelona, Spain.

The company is preparing to launch Nerivio at the Neurological Association of South Africa annual congress on April 17, 2024. Additionally, Nerivio will be showcased at the International Headache Society 2024 iHEAD meeting in Berlin in May 2024. Subsequent launches are planned for Spain and the UK.

“At a time when conversations on migraine focus on migraine5 as a women’s health issue, relief from migraine through the use of technology and drug-free solutions, challenges associated with managing migraine during the child-bearing age, and distinguishing migraine from headache, we are happy to take our clinically-proven first digital therapeutics product, Nerivio, to patients in our identified markets”, said M.V. Ramana, chief executive officer, Branded Markets (India and Emerging Markets), Dr. Reddys.

According to the reports, migraine is a global health challenge that affects around 30% of adults on 15 or more days per month, impacting 1.7% to 4% of the population. The current best estimate of global migraine prevalence is 14–15%.

In India, around 213 million people suffer from the condition out of which 60% are women, according to the reports. In Germany, around 8 to 10 million people in Germany are affected due to migraine.

Dr. Reddy’s launched Nerivio in India in 2023. The device is supported by Dr. Reddy’s patient support programme called ‘M-Free’.

“The programme is a comprehensive support system that enhances and streamlines the journey of the patients. M-Free includes services such as onboarding and counseling of patients, device demonstrations, doorstep delivery, flexible payment options, informative content, and dedicated customer care to help patients get the most out of the device,” the company said in a statement.

Last year, the company entered into an exclusive agreement with Theranica, a prescribed digital therapeutics company, for the marketing and distribution of Nerivio across various markets.

“Nerivio has had an encouraging start in India, with recommendation from neurologists in India and bringing relief to patients living with migraine. We believe this product meets a genuine unmet clinical need among migraine patients, and has the potential to reduce pill burden in migraine”, said Ramana.